Alberto Martini: Influence Statistics

Alberto Martini

Alberto Martini

Dipartimento di Neuroscienze, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, ITALY | Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, ...

Alberto Martini: Expert Impact

Concepts for which Alberto Martini has direct influence: Juvenile idiopathic arthritis , Idiopathic arthritis , Juvenile idiopathic , Inactive disease , Juvenile dermatomyositis , Juvenile child child , Radiographic progression .

Alberto Martini: KOL impact

Concepts related to the work of other authors for which for which Alberto Martini has influence: Juvenile idiopathic arthritis , Lupus nephritis , Macrophage activation syndrome , Autoimmune diseases , Familial mediterranean fever , Patients jia .

KOL Resume for Alberto Martini


Dipartimento di Neuroscienze, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, ITALY


A. Martini, MD, IRCCS Istituto G Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy and Università di Genova, Genoa, Italy.

Università di Genova, Genova, Italy


IRCCS Istituto Giannina Gaslini, Ospedale Pediatrico Gaslini, Genoa, Italy


Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Sciences, University of Genoa, Genoa, Italy

University of Genoa and G. Gaslini Institute, Genoa, United States of America


“G. Gaslini” Institute, Scientific Direction, University of Genoa, Genoa, Italy

A. Martini, MD, Professor, IRCCS Istituto Giannina Gaslini, Direzione Scientifica; A. Ravelli, MD, Professor, IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia and Università degli Studi di Genova; T. Avcin, MD, PhD, University Children's Hospital, University Medical Center Ljubljana, Department of Allergology, Rheumatology and Clinical Immunology; M.W. Beresford, MBChB, PhD, Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, and Institute of Translational Medicine, University of Liverpool; R. Burgos-Vargas, MD, Hospital General de Mexico, Departamento de Reumatología; R. Cuttica, MD, Hospital Pedro de Elizalde, Rheumatology Section; N.T. Ilowite, MD, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Pediatrics; R. Khubchandani, MD, Jaslok Hospital and Research Centre, Department of Paediatrics; R.M. Laxer, MD, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto; D.J. Lovell, MD, MPH, Cincinnati Children's Hospital Medical Center, Division of Rheumatology; R.E. Petty, MD, PhD, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia; C.A. Wallace, MD, Seattle Children's Hospital; N.M. Wulffraat, MD, PhD, Wilhelmina Children's Hospital, Department of Pediatric Immunology and Rheumatology; A. Pistorio, MD, PhD, IRCCS Istituto Giannina Gaslini, Servizio di Epidemiologia e Biostatistica; N. Ruperto, MD, MPH, IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO.


Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy

Istituto Giannina Gaslini, Pediatria II - Reumatologia, PRINTO.


IRCCS Istituto G. Gaslini, Pediatria II, Genova, Italy

Prominent publications by Alberto Martini

KOL-Index: 16018 . OBJECTIVES: To validate the previously proposed classification criteria for Henoch-Schönlein purpura (HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener granulomatosis (c-WG) and c-Takayasu arteritis (c-TA). METHODS: Step 1: retrospective/prospective web-data collection for children with HSP, c-PAN, c-WG and c-TA with age at diagnosis
Known for Classification Criteria | Childhood Takayasu | Henoch–schönlein Purpura | Ankara 2008
KOL-Index: 15181 . BACKGROUND: Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis. METHODS: Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with ...
Known for Juvenile Rheumatoid Arthritis | Adalimumab Methotrexate | Monoclonal Antibodies | Acr Pedi
KOL-Index: 14879 . OBJECTIVE: To develop response criteria for juvenile dermatomyositis (DM). METHODS: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. ...
Known for Major Clinical | Core Measures | Juvenile Dermatomyositis | Rheumatology International
KOL-Index: 14540 . OBJECTIVE: To validate and promulgate a core set of outcome measures for the evaluation of response to treatment in patients with juvenile systemic lupus erythematosus (SLE). METHODS: In 2001, a preliminary consensus-derived core set of measures for evaluating the response to therapy in juvenile SLE was established. In the present study, the core set was validated through an ...
Known for Response Therapy | Lupus Erythematosus | Prospective Validation | Juvenile Systemic
KOL-Index: 14464 . BACKGROUND: Some children with juvenile idiopathic arthritis either do not respond, or are intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour necrosis factor (TNF) drugs. We aimed to assess the safety and efficacy of abatacept, a selective T-cell costimulation modulator, in children with juvenile idiopathic arthritis who had failed previous ...
Known for Juvenile Idiopathic Arthritis | Patients Abatacept | 6 Months | Withdrawal Trial
KOL-Index: 14461 . BACKGROUND: Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials. METHODS: In trial 1, we randomly assigned patients, 2 to 19 years of age, with systemic JIA and active systemic features (fever; ≥2 active joints; ...
Known for Canakinumab Patients | Monoclonal Antibodies | Systemic Jia | Humanized Arthritis
KOL-Index: 14258 . OBJECTIVE: Bone marrow-derived mesenchymal stem cells (BM-MSCs) are multipotent cells characterized by immunomodulatory properties and are therefore considered a promising tool for the treatment of immune-mediated diseases. This study was undertaken to assess the influence of murine BM-MSCs on the activation of B cells in (NZB × NZW)F(1) mice as an animal model of systemic lupus ...
Known for Bone Marrow | Systemic Lupus Erythematosus | Murine Model | Cell Activation
KOL-Index: 13763 . OBJECTIVE: To investigate the level of agreement between patients, mothers, fathers, and physicians in rating pain intensity in juvenile idiopathic arthritis (JIA), and to identify factors explaining discrepancies between raters. METHODS: Ninety-four children with JIA and their mothers and fathers were asked to rate independently the intensity of present pain and pain in the previous week ...
Known for Pain Children | Juvenile Idiopathic Arthritis | Mothers Fathers | Level Agreement
KOL-Index: 13620 . OBJECTIVE: To use the Pediatric Rheumatology International Trials Organization (PRINTO) core set of outcome measures to develop a validated definition of improvement for the evaluation of response to therapy in juvenile systemic lupus erythematosus (SLE). METHODS: Thirty-seven experienced pediatric rheumatologists from 27 countries, each of whom had specific experience in the assessment of ...
Known for Lupus Erythematosus | Provisional Criteria | Juvenile Systemic | Rheumatology International
KOL-Index: 13416 . OBJECTIVE: To analyze the long-term impact of the R92Q mutation of TNFRSF1A in children with periodic fever, in comparison with children with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with TNFRSF1A structural mutations and children with periodic fever of unknown origin fulfilling the criteria for periodic fever, aphthosis, pharyngitis, and adenitis syndrome ...
Known for R92q Mutation | Tnfrsf1a Gene | Periodic Fever | Traps Patients
KOL-Index: 13279 . The aim of the study was to characterise CCR7+ and CCR7- memory T cells infiltrating the inflamed joints of patients with juvenile idiopathic arthritis (JIA) and to investigate the functional and anatomical heterogeneity of these cell subsets in relation to the expression of the inflammatory chemokine receptors CXCR3 and CCR5. Memory T cells freshly isolated from the peripheral blood and ...
Known for Juvenile Idiopathic Arthritis | Memory Cells | Patients Jia | Ccr7 Receptors
KOL-Index: 13155 . CONTEXT: Novel therapies have improved the remission rate in chronic inflammatory disorders including juvenile idiopathic arthritis (JIA). Therefore, strategies of tapering therapy and reliable parameters for detecting subclinical inflammation have now become challenging questions. OBJECTIVES: To analyze whether longer methotrexate treatment during remission of JIA prevents flares after ...
Known for 12 Months | Methotrexate Withdrawal | Patients Jia | Juvenile Idiopathic Arthritis
KOL-Index: 13026 . CC chemokine ligand 1 (CCL1; I-309) is a CC chemokine that interacts with CC chemokine receptor 8, which is preferentially expressed in polarized T helper cell type 2 and Tc2 cells, in eosinophils, and in T regulatory cells. The present study, prompted by transcriptional profiling of human monocytes undergoing different forms of activation, was designed to characterize the production of ...
Known for Human Monocytes | Chemokine Production | Type 2 | Fcγ Receptor

Key People For Juvenile Idiopathic Arthritis

Top KOLs in the world
Ross Edward Petty
juvenile idiopathic arthritis systemic lupus erythematosus rubella virus
Anne Marie Prieur
juvenile chronic arthritis body composition growth hormone
Taunton R Southwood
juvenile idiopathic arthritis young people united kingdom
David N Glass
juvenile rheumatoid arthritis gene expression calcium supplementation
Alberto Martini
juvenile idiopathic arthritis inactive disease macrophage activation syndrome
Prudence Joan Manners
juvenile arthritis growing pains severe hemophilia

Dipartimento di Neuroscienze, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, ITALY | Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy |